Followers | 446 |
Posts | 31415 |
Boards Moderated | 4 |
Alias Born | 04/04/2006 |
Sunday, March 01, 2015 1:55:57 PM
Benzinga
By David Fabian February 25, 2015 3:06 PM
Biotechnology ETFs have leapt out of the gate in 2015 with another strong spurt of momentum that has catapulted them to the top of sector rankings. The unequivocal asset leader in this category is the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which has more than $8 billion under management.
IBB has gained more than 12 percent so far this year and continues to shine as an industry-leading benchmark. This performance, while impressive, is still a far cry from several specialized biotech ETFs with unique index construction methodologies.
ALPS Medical Breakthroughs
The relatively new ALPS Medical Breakthroughs ETF (NYSE: SBIO) was released on the last day of 2014 and has achieved an impressive return of nearly 18 percent this year.
This ETF focuses on 75 small- and mid-cap biotechnology and pharmaceutical companies with a weighted-average market cap of $2 billion. SBIO has $17 million in total assets and charges an expense ratio of 0.50 percent.
Related Link: JPM Securities Picks Through Biotech News For Winners
This ETF is designed for those seeking more aggressive or early-stage biotech companies with a smaller footprint than the larger stocks that dominate an index like IBB. In addition, the inherent diversification in SBIO can be more advantageous than researching and investing in individual companies.
sbio.png
SPDR S&P Biotech
Another standout in the biotech space has been the SPDR S&P Biotech (ETF) (NYSE: XBI), which has gained more than 16 percent this year.
XBI relies on a modified equal-weighted methodology to distribute $2 billion in assets to 88 underlying stocks. This allows for smaller companies within the index to have a much greater pull on the total performance of the fund than traditional market-cap weighted strategies.
This ETF charges an expense ratio of 0.35 percent annually, as well.
XBI still has exposure to top companies such as Gilead Sciences, Inc. (NASDAQ: GILD) and Celgene Corporation (NASDAQ: CELG). However, it also beckons niche companies – such Foundation Medicine Inc (NASDAQ: FMI) – from all major U.S. exchanges.
The variances in this menu of ETFs highlight the significance of index construction on overall returns. Right now, smaller biotechnology companies are a driving force of outperformance, but that may change as conditions evolve.
See more from Benzinga
3 ETFs For Dividend Growth Investors
Japan, Natural Gas And NASDAQ Composite ETFs To Watch This Week
Best And Worst ETFs Of The Week Amid Greek Relief Deal
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
http://finance.yahoo.com/news/best-biotech-etf-isnt-always-200619744.html?soc_src=copy
YOU agree to all this when reading my posts
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105604276
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105604289
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM